Microbiome Invest 2019 | Kisaco Research
Promoting partnerships and showcasing the latest innovation in the microbiome field
London
23 May, 2019
Download Agenda
The Audience
Register

Why Attend

The Microbiome Invest Congress 2019 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and health companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space. 

“The human microbiome market is expected to reach USD 658 Million by 2023 from USD 294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019–2023)” Human Microbiome Market Industry Report

90+
Delegates
4+
Hours of Dedicated Networking
9
Emerging Innovators Pitching
3
Key challenges covered
10+
Industry leading presenters

Pitch Your Microbes

This year's MICROBIOME INVEST ‘Pitch Your Microbes’ platform will provide nine of the most exciting emerging companies in microbiome the opportunity to pitch their innovative ideas to a room full of potential advisors, investors and partners. The final nine presenting companies will be handpicked by our esteemed selection comittee, who you can see below. 

Microbiome Invest Committee

CLICK HERE TO PITCH YOUR MICROBES

The deadline for submissions is the 25th of March, make sure you don't miss out on this incredible opportunity.

Last Year's 'Pitch Your Microbes' Finalists

Dominik Burziwoda

CEO
Perfood GmbH

Evelina Vågesjö, PhD MBA

CEO
Ilya Pharma

Kristofer Cook

CEO & Co-Founder
Carbiotix

Grégory Lambert

CEO & VP, R&D
TargEDys SA

Mats Wallstrom

CEO
Lavivo

Richard Andrews

CEO
Azitra

Gregory McKenzie, Ph.D.

Vice President of Research and CSO
ConsortiaTX

Dr Soren Krogsgaard Thomsen

CEO
BioMe Oxford

Dr Luis Gosalbez

Director of Business Development
OptiBiotix Ltd

Dr Elran Haber

CEO
Biomica

This Year's Speakers

 

Dr Phil Bolton

Outside Innovation Officer - Health
Reckitt Benckiser

Phil obtained his Ph.D in organometallic chemistry from the University of Durham in 2000 and subsequently joined P&G where he worked on new technology development for the hair colourant category. Phil then joined RB in 2006 and has worked across a number of Innovation and Category R&D ROLES IN THE UK, Italy, Singapore and the US, becoming a director in 2010 and returning back to the UK based RB HQ in April 2015.

Dr Phil Bolton

Outside Innovation Officer - Health
Reckitt Benckiser

Phil obtained his Ph.D in organometallic chemistry from the University of Durham in 2000 and subsequently joined P&G where he worked on new technology development for the hair colourant category. Phil then joined RB in 2006 and has worked across a number of Innovation and Category R&D ROLES IN THE UK, Italy, Singapore and the US, becoming a director in 2010 and returning back to the UK based RB HQ in April 2015.

Phil currently leads the Outside Innovation team and has responsibility for delivering new and innovative solutions to the Health category pipelines. This can be anything from an ingredient in the product, through to products themselves, forging sustainable partnerships as well as being a strategic innovation partner for the senior category leadership within RB.

 

Anna Williamson

Director, Oncology BusinessDevelopment & Head of UK Business Development
Genentech Partnering

Anna Williamson is a member of Roche and Genentech’s partnering group.  Anna is based in Cambridge, UK and is responsible for sourcing and evaluating new collaboration opportunities and executing strategic alliances in all areas of interest to Roche and Genentech, with an increasing focus on UK/European companies.  Anna joined Genentech in San Francisco in 2004 and moved to Cambridge in 2017 to establish a partnering presence in the UK.

Anna Williamson

Director, Oncology BusinessDevelopment & Head of UK Business Development
Genentech Partnering

Anna Williamson is a member of Roche and Genentech’s partnering group.  Anna is based in Cambridge, UK and is responsible for sourcing and evaluating new collaboration opportunities and executing strategic alliances in all areas of interest to Roche and Genentech, with an increasing focus on UK/European companies.  Anna joined Genentech in San Francisco in 2004 and moved to Cambridge in 2017 to establish a partnering presence in the UK. Prior to joining Genentech, Anna worked for the University of California Office of Technology Transfer where she was a member of the life-sciences team, responsible for managing and out-licensing a portfolio of life sciences inventions from multiple UC campuses.  Anna holds a BA in Natural Sciences (Neuroscience) and a PhD in Neuroscience, both from the University of Cambridge and carried out post-doctoral research at the University of Colorado and UCSF.

 

Artem Khlebnikov

Strategic Partnerships Director
Danone Nutricia Research

Artem Khlebnikov is Strategic Partnerships Director at the Danone Nutricia Research. In his role, he works closely with public and private partners and Danone R&I colleagues brining open innovation  to help drive science-based opportunities that activate the Danone’s alimentation strategy and enable significant and sustainable growth opportunities aligned with Danone’s #OneHealth.OnePlanet approach.

Artem Khlebnikov

Strategic Partnerships Director
Danone Nutricia Research

Artem Khlebnikov is Strategic Partnerships Director at the Danone Nutricia Research. In his role, he works closely with public and private partners and Danone R&I colleagues brining open innovation  to help drive science-based opportunities that activate the Danone’s alimentation strategy and enable significant and sustainable growth opportunities aligned with Danone’s #OneHealth.OnePlanet approach.

Artem holds an MS degree in Chemical Engineering from the Mendeleev University of Chemical Technology, Moscow Russia, has completed his PhD in Biotechnology at the Swiss Federal institute of Technology in Lausanne and received Post-Doctoral training in Molecular Biology at University of California at Berkeley, USA.

 

Craig Thomson

Partner
HGF Limited

Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients and in relation to biotechnological and pharmaceutical fields.  As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding/acquisition due diligence, and advising on aggressive/defensive strategies in relation to third party IP. He has a particular interest in inventions relating to the microbiome, including bacteriophage.

Craig Thomson

Partner
HGF Limited

Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients and in relation to biotechnological and pharmaceutical fields.  As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding/acquisition due diligence, and advising on aggressive/defensive strategies in relation to third party IP. He has a particular interest in inventions relating to the microbiome, including bacteriophage.

 

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Dr Andrew Morgan, DuPont Fellow and Chief Scientist, DuPont Nutrition & Health Over 35 years’ experience in research and development including  human health & nutrition, animal nutrition, industrial enzymes and crop science as well as innovation management, business development and corporate venturing including founding member of DuPont Nutrition & Health’s Microbiome Venture

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Dr Andrew Morgan, DuPont Fellow and Chief Scientist, DuPont Nutrition & Health Over 35 years’ experience in research and development including  human health & nutrition, animal nutrition, industrial enzymes and crop science as well as innovation management, business development and corporate venturing including founding member of DuPont Nutrition & Health’s Microbiome Venture

 

Johan van Hylckama Vlieg

Vice President Microbiome & Human Health Innovation
Chr. Hansen A/S

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

Johan van Hylckama Vlieg

Vice President Microbiome & Human Health Innovation
Chr. Hansen A/S

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

 

John Hambor

Director of Research Beyond Borders
Boehringer Ingelheim

John Hambor

Director of Research Beyond Borders
Boehringer Ingelheim
 

Jonathan Gilbert

Global Commercial Lead Microbiome GI Health
Nestlé Health Science

Jonathan Gilbert

Global Commercial Lead Microbiome GI Health
Nestlé Health Science
 

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a trans-national group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D. Mike is highly experienced in the biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.

Agenda

You can download our latest agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

 

Microbiome Invest 2019, agenda

Event Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Host

Partners

Media Partners

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Saturday, March 16, 2019 to Friday, April 5, 2019
Academics, Biotech companies (Pre-Series A Investment), and Angel Investors
£599 +VAT
EARLY BIRD RATE - book before 5th April
Main Conference
Post-Show Access to Presentations
Complimentary Articles and Content
Saturday, March 16, 2019 to Friday, April 5, 2019
Pharmaceutical, nutrition and biotech companies (Post-Series A), Venture Capital Investors
£1,599 + VAT
EARLY BIRD RATE - book before 5th April
Main Conference
Post-Show Access to Presentations
Complimentary Articles and Content
Saturday, March 16, 2019 to Friday, April 5, 2019
Vendors (including Investment bankers, Lawyers, Consultants) and Private Equity
£1,899 + VAT
EARLY BIRD RATE - book before 5th April
Main Conference
Post-Show Access to Presentations
Complimentary Articles and Content
Preparing registration...

Book a Team to Save More!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

 

Enquiries about our pricing categories

Contact our team [email protected] or phone us on 02036962920 for more details.

Venue

Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London SW7 4LH

The 3rd Annual Microbiome Invest Congress will be taking place at The Millennium Gloucester Hotel, who are also providing accommodation for our delegates.

Book with the code MICR230519 before the 22nd of May to receive the discounted room price of £200.

To book, you can either:

  • Contact the direct reservations line on +44 207 331 6195
  • Contact the main hotel line on +44 207 373 6030
  • Contact the resevervations email: [email protected]

You can find out more about the hotel by clicking the image below.

Millennium Gloucester Hotel

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.